Security Snapshot

Faeth Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FTH) Institutional Ownership

CUSIP: 81728A207

13F Institutional Holders and Ownership History from Q1 2025 to Q2 2026

Latest Period

Q2 2026

Institutions Reporting

44

Shares (Excl. Options)

13,045,340

Price

$25.00

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Stock, par value $0.0001 per share
Symbol
FTH on Nasdaq
All holders as of 30 Jun 2026
Q2 2026
Total 13F shares
13,045,340
Latest holder snapshot 5 signals
Total 13F value
$326,133,726
Portfolio coverage rank
0%
Share change
+11,194,993
Value change
+$276,806,304
Number of holders
44
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
25,766,750
SEC-reported price per share
$29.38
Insider filing price
$29.38
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • FTH - Faeth Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 81728A207.
  • 44 institutions reported positions in Q2 2026.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 30 to 44 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $67,971,428 to $326,133,726.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 44 institutions filings for Q2 2026.

Open SEC evidence

Security key

81728A207

Latest holder period

Q2 2026

13F holders

44

13D/G owners

6

CIK / CUSIP context first

Open Q2 2026 holders FTH full holder history Faeth Therapeutics, Inc. SEC filings Faeth Therapeutics, Inc. company facts Faeth Therapeutics, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
6
Security
FTH
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Khosla Ventures VI, L.P. 10% $95,181,509 2,632,232 VK Services, LLC 15 Jun 2026
S2G Investments, LLC 10% $45,301,304 2,575,401 S2G Investments, LLC 15 Jun 2026
SUVRETTA CAPITAL MANAGEMENT, LLC 7.8% $35,533,612 2,020,103 Suvretta Capital Management, LLC 15 Jun 2026
Caligan Partners LP 2.4% -78% $22,761,527 +$18,205,294 629,467 +400% Caligan Partners LP 30 Jun 2026
Trails Edge Capital Partners, LP 2% -79% $18,634,514 +$14,077,992 515,335 +309% Trails Edge Capital Partners, LP 30 Jun 2026
MILLENNIUM MANAGEMENT LLC 3.1% -65% $876,106 -$1,838,176 41,561 -68% ICS Opportunities II LLC 01 Jun 2026

As of 30 Jun 2026, 44 institutional investors reported holding 13,045,340 shares of Faeth Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FTH). This represents 51% of the company’s total 25,766,750 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
50%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
MONTANOVA CAPITAL, LLC 7.8% 2,020,103 +5747% 1.1% $50,502,575
Avoro Capital Advisors LLC 5.6% 1,444,039 0.32% $36,100,975
BAKER BROS. ADVISORS LP 5% 1,286,411 0.16% $32,160,275
Balyasny Asset Management L.P. 4% 1,042,198 +6331% 0.05% $26,054,950
Vivo Capital, LLC 2.8% 722,020 0% 1.6% $18,050,500
Logos Global Management LP 2.8% 722,020 +2307% 0.78% $18,050,500
Fairmount Funds Management LLC 2.8% 722,020 1.2% $18,050,500
RA CAPITAL MANAGEMENT, L.P. 2.8% 722,020 0.16% $18,050,500
Caligan Partners LP 2.4% 629,467 +400% 0.76% $15,736,675
B Group, Inc. 2.4% 610,169 8.7% $15,254,225
Trails Edge Capital Partners, LP 2% 515,335 +312% 2% $12,883,375
FRANKLIN RESOURCES INC 1.9% 494,516 +270% 0% $12,362,900
Octagon Capital Advisors LP 1.4% 361,010 0.83% $9,025,250
ADAR1 Capital Management, LLC 1.4% 361,010 0.43% $9,025,250
MARSHALL WACE, LLP 0.8% 206,508 +214% 0% $5,162,700
Boxer Capital Management, LLC 0.7% 180,505 0.34% $4,512,625
Patient Square Capital LP 0.68% 175,050 0.68% $4,376,250
Alyeska Investment Group, L.P. 0.56% 144,404 0.01% $3,610,100
Affinity Asset Advisors, LLC 0.56% 144,404 0.18% $3,610,100
BOOTHBAY FUND MANAGEMENT, LLC 0.52% 133,643 +412% 0.06% $3,341,075
AWM Investment Company, Inc. 0.43% 111,343 0.24% $2,783,575
Richmond Investment Services, LLC 0.31% 79,731 0.63% $1,993,275
Ikarian Capital, LLC 0.14% 35,386 +457% 0.15% $884,650
UBS Group AG 0.08% 21,541 +376% 0% $538,525
RENAISSANCE TECHNOLOGIES LLC 0.08% 20,416 -36% 0% $510,400

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
6
Latest
Q2 2026
Rows shown
1-6 of 6
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 13,045,340 $326,133,726 +$276,806,304 $25.00 44
2026 Q1 2,156,465 $67,971,428 +$66,014,101 $31.52 30
2025 Q4 48,247 $514,780 -$10,572 $10.67 10
2025 Q3 49,335 $466,215 -$168,686 $9.45 9
2025 Q2 69,928 $599,982 +$593,398 $8.58 10
2025 Q1 16,514 $6,507 +$6,507 $0.39 1
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .